TS/A is a mouse mammary adenocarcinoma cell line established in the early 1980s from a spontaneous tumor of a retired breeder BALB/c female mouse.[1][2] In the 1990s it was widely used as a recipient cell line for the transduction of cytokine genes and other genes of immunological interest, to produce recombinant experimental vaccines that induced anti-tumor immunological responses.[3]
References
edit- ^ Nanni P, C De Giovanni, P-L Lollini, G Nicoletti, and G Prodi. 1983. "TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma". Clinical and Experimental Metastasis. 1(4): 373-80.
- ^ De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini PL, Nanni P. "Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model". Cancers (Basel). 2019 Nov 27;11(12).
- ^ Allione A, M Consalvo, P Nanni, P-L Lollini, F Cavallo, M Giovarelli, M Forni, A Gulino, MP Colombo, P Dellabona, H Hock, T Blankenstein, FM Rosenthal, B Gansbacher, MC Bosco, T Musso, L Gusella, and Guido Forni. 1994. "Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants". Cancer Research. 54(23): 6022-6026.
External links
edit
 | This cell biology article is a stub. You can help Wikipedia by expanding it. |